Secondary Prevention in Coronary Heart Disease
Information source: Sorlandet Hospital HF
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coronary Heart Disease
Intervention: smoking cessation (Behavioral); betablocker, diuretics, ACEI, ARB, moxonidine (Drug); statins (simvastatin, atorvastatin), ezetimib (Drug); training (Behavioral); influenzavaccine (Biological); metformin, glimepiride, insulin (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Sorlandet Hospital HF Official(s) and/or principal investigator(s):
Serena Tonstad, dr.med., Study Chair, Affiliation: Ullevaal University Hospital
Overall contact:
Jarle Jortveit, MD, Phone: 004737014000, Email: jarle.jortveit@sshf.no
Summary
Secondary prevention in coronary heart disease
Clinical Details
Official title: Secondary Prevention in Coronary Heart Disease
Study design: Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Risk factor reduction
Detailed description:
Risk factor reduction in coronary heart disease
Eligibility
Minimum age: 18 Years.
Maximum age: 79 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- acute myocardial infarction, CABG or PCI
Exclusion Criteria:
- Age < 18 and age > 80
- pregnant
- critical illness
- drug abuse
Locations and Contacts
Jarle Jortveit, MD, Phone: 004737014000, Email: jarle.jortveit@sshf.no
Sorlandet Hospital, Arendal, Norway; Recruiting
Jarle Jortveit, MD, Phone: 00473714000, Email: jarle.jortveit@sshf.no
Additional Information
Starting date: September 2007
Ending date: December 2012
Last updated: May 14, 2008
|
